- Indivior said Tuesday a U.S. court had denied its appeal against a decision that would lift a ban preventing rival Dr. Reddy's Laboratories from selling a generic version of the company's opioid addiction treatment.

Indivior said it would file an emergency request to keep the ban in place pending resolution of its forthcoming application for an administrative stay to the Supreme Court of the United States.

The U.S. Court of Appeals for the Federal Circuit had denied Indivior's appeal on February 11, and ordered that the rival Dr. Reddy's Laboratories be granted the right to sell a generic version of the company's opioid treatment on February 19, 2019.

'After the mandate issues, Dr. Reddy's Laboratories and Alvogen Pine Brook will no longer be prevented from selling, offering to sell, or importing their generic buprenorphine/naloxone sublingual film product,' Indivior said.

Story provided by